Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 67.22 Billion KRW | 5.08% |
| 2022 | 63.25 Billion KRW | 16.13% |
| 2021 | 54.47 Billion KRW | -15.95% |
| 2020 | 64.8 Billion KRW | 22.31% |
| 2019 | 52.98 Billion KRW | 8.56% |
| 2018 | 48.8 Billion KRW | -5.17% |
| 2017 | 51.47 Billion KRW | -4.29% |
| 2016 | 53.78 Billion KRW | 1.9% |
| 2015 | 52.77 Billion KRW | 11.89% |
| 2014 | 47.16 Billion KRW | -1.27% |
| 2013 | 47.77 Billion KRW | 7.58% |
| 2012 | 44.4 Billion KRW | -0.86% |
| 2011 | 44.79 Billion KRW | -30.8% |
| 2010 | 64.73 Billion KRW | 7.66% |
| 2009 | 60.12 Billion KRW | -11.04% |
| 2008 | 67.58 Billion KRW | 17.09% |
| 2007 | 57.72 Billion KRW | 0.5% |
| 2006 | 57.43 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 20.79 Billion KRW | 20.98% |
| 2024 Q2 | 19.46 Billion KRW | -6.43% |
| 2023 Q1 | 16.04 Billion KRW | 4.88% |
| 2023 Q4 | 17.19 Billion KRW | 9.96% |
| 2023 FY | 66.46 Billion KRW | 5.08% |
| 2023 Q3 | 15.63 Billion KRW | -14.16% |
| 2023 Q2 | 18.21 Billion KRW | 13.52% |
| 2022 FY | 63.25 Billion KRW | 16.13% |
| 2022 Q1 | 17.57 Billion KRW | 29.62% |
| 2022 Q4 | 15.29 Billion KRW | 4.54% |
| 2022 Q2 | 15.75 Billion KRW | -10.38% |
| 2022 Q3 | 14.63 Billion KRW | -7.1% |
| 2021 Q1 | 12.5 Billion KRW | -1.89% |
| 2021 Q2 | 13.73 Billion KRW | 9.85% |
| 2021 Q3 | 14.67 Billion KRW | 6.83% |
| 2021 Q4 | 13.55 Billion KRW | -7.6% |
| 2021 FY | 54.47 Billion KRW | -15.95% |
| 2020 Q3 | 15.67 Billion KRW | -16.06% |
| 2020 Q2 | 18.67 Billion KRW | 5.47% |
| 2020 FY | 64.8 Billion KRW | 22.31% |
| 2020 Q1 | 17.7 Billion KRW | 29.25% |
| 2020 Q4 | 12.74 Billion KRW | -18.71% |
| 2019 Q3 | 12.3 Billion KRW | -10.32% |
| 2019 FY | 52.98 Billion KRW | 8.56% |
| 2019 Q1 | 13.25 Billion KRW | 2.61% |
| 2019 Q2 | 13.72 Billion KRW | 3.55% |
| 2019 Q4 | 13.7 Billion KRW | 11.32% |
| 2018 FY | 48.8 Billion KRW | -5.17% |
| 2018 Q4 | 12.91 Billion KRW | 5.12% |
| 2018 Q3 | 12.28 Billion KRW | 3.9% |
| 2018 Q2 | 11.82 Billion KRW | 0.39% |
| 2018 Q1 | 11.77 Billion KRW | 3.09% |
| 2017 Q4 | 11.42 Billion KRW | -12.83% |
| 2017 Q1 | 13.39 Billion KRW | 9.12% |
| 2017 FY | 51.47 Billion KRW | -4.29% |
| 2017 Q2 | 13.54 Billion KRW | 1.14% |
| 2017 Q3 | 13.1 Billion KRW | -3.22% |
| 2016 Q4 | 12.27 Billion KRW | -7.89% |
| 2016 Q1 | 13.27 Billion KRW | 7.21% |
| 2016 Q2 | 14.9 Billion KRW | 12.27% |
| 2016 Q3 | 13.32 Billion KRW | -10.6% |
| 2016 FY | 53.78 Billion KRW | 1.9% |
| 2015 Q3 | 11.4 Billion KRW | -22.12% |
| 2015 Q4 | 12.38 Billion KRW | 8.63% |
| 2015 FY | 52.77 Billion KRW | 11.89% |
| 2015 Q1 | 14.35 Billion KRW | 24.71% |
| 2015 Q2 | 14.63 Billion KRW | 1.98% |
| 2014 Q1 | 10.92 Billion KRW | -11.9% |
| 2014 Q4 | 11.51 Billion KRW | -14.74% |
| 2014 Q3 | 13.5 Billion KRW | 20.26% |
| 2014 Q2 | 11.22 Billion KRW | 2.71% |
| 2014 FY | 47.16 Billion KRW | -1.27% |
| 2013 Q1 | 12.63 Billion KRW | 158.76% |
| 2013 FY | 47.77 Billion KRW | 7.58% |
| 2013 Q3 | 11.19 Billion KRW | -2.92% |
| 2013 Q4 | 12.4 Billion KRW | 10.78% |
| 2013 Q2 | 11.53 Billion KRW | -8.67% |
| 2012 Q4 | 4.88 Billion KRW | -57.98% |
| 2012 FY | 44.4 Billion KRW | -0.86% |
| 2012 Q2 | 10.17 Billion KRW | -42.06% |
| 2012 Q3 | 11.61 Billion KRW | 14.23% |
| 2012 Q1 | 17.55 Billion KRW | 0.0% |
| 2011 Q3 | 14.77 Billion KRW | 24.05% |
| 2011 Q1 | 17.42 Billion KRW | 9.19% |
| 2011 Q2 | 11.9 Billion KRW | -31.68% |
| 2011 FY | 44.79 Billion KRW | -30.8% |
| 2010 Q4 | 15.95 Billion KRW | 2.55% |
| 2010 FY | 64.73 Billion KRW | 7.66% |
| 2010 Q1 | 13.62 Billion KRW | -12.46% |
| 2010 Q2 | 15.78 Billion KRW | 15.84% |
| 2010 Q3 | 15.56 Billion KRW | -1.4% |
| 2009 Q2 | 15.53 Billion KRW | -0.34% |
| 2009 Q3 | 15.39 Billion KRW | -0.92% |
| 2009 Q4 | 15.56 Billion KRW | 1.09% |
| 2009 FY | 60.12 Billion KRW | -11.04% |
| 2009 Q1 | 15.59 Billion KRW | -14.48% |
| 2008 Q3 | 16.56 Billion KRW | -3.68% |
| 2008 FY | 67.58 Billion KRW | 17.09% |
| 2008 Q2 | 17.19 Billion KRW | 27.71% |
| 2008 Q4 | 18.23 Billion KRW | 10.07% |
| 2008 Q1 | 13.46 Billion KRW | -5.28% |
| 2007 Q3 | 15.09 Billion KRW | 1.07% |
| 2007 FY | 57.72 Billion KRW | 0.5% |
| 2007 Q2 | 14.94 Billion KRW | 0.0% |
| 2007 Q4 | 14.21 Billion KRW | -5.85% |
| 2006 FY | 57.43 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -44.553% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 81.537% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 66.2% |
| HANDOK Inc. | 151.36 Billion KRW | 55.588% |
| Yuhan Corporation | 564.5 Billion KRW | 88.091% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 79.137% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -183.086% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 91.957% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 10.414% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 66.212% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -65.376% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 28.875% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 52.274% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -44.553% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -93.643% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 12.489% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 658.083% |
| JW Holdings Corporation | 446.15 Billion KRW | 84.933% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 67.609% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 89.742% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 79.973% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 14.494% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 10.651% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 6.906% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 63.428% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -44.553% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 77.221% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 90.137% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 79.973% |
| Yuhan Corporation | 564.5 Billion KRW | 88.091% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 66.691% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | 5.236% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 32.115% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 79.973% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 53.922% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 61.251% |
| CKD Bio Corp. | 5.01 Billion KRW | -1241.727% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 73.558% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 63.49% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 31.491% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 14.494% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 81.904% |
| Boryung Corporation | 333.26 Billion KRW | 79.829% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -34.327% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 66.212% |
| JW Lifescience Corporation | 51.32 Billion KRW | -30.978% |